<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513526</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-052</org_study_id>
    <secondary_id>CDR0000559149</secondary_id>
    <secondary_id>U01CA121947</secondary_id>
    <nct_id>NCT00513526</nct_id>
  </id_info>
  <brief_title>Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection</brief_title>
  <official_title>A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from human papillomavirus may help the body build an effective
      immune response to kill HIV cells.

      PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus
      vaccine therapy works in treating men with HIV-1 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the safety and tolerability of quadrivalent human papillomavirus (HPV) (types
           6, 11, 16, 18) recombinant vaccine in HIV-infected men.

        -  To assess the immunogenicity of the quadrivalent HPV vaccine for types 6, 11, 16 and 18
           in subjects who are antibody-negative at baseline.

      Secondary

        -  To evaluate the changes in plasma HIV-1 RNA and CD4+ count after the vaccination series.

        -  To describe the associations of CD4+ count, nadir CD4+ count, and age on antibody
           response.

        -  To evaluate the levels and persistence of HPV 6, 11, 16, and 18 antibody titers after
           the vaccination series among subjects according to serostatus at baseline.

        -  To evaluate the oral levels of serum IgA before and after the vaccination series.

      Tertiary

        -  To evaluate prevalent and incident HPV infections in the anal canal.

        -  To evaluate cytological and histological abnormalities in the anal canal.

        -  To evaluate prevalent and incident HPV infections in the oral cavity.

        -  To compare oral and anal compartmental shedding of HPV before and after vaccination.

      OUTLINE: This is a multicenter study.

      Patients receive quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
      intramuscularly on day 0 and weeks 8 and 24.

      After completion of protocol therapy, patients are followed at 7, 12, and 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine</measure>
    <time_frame>All study visits</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detectable Human Papillomavirus (HPV) Antibody to Type 6 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 6 at Baseline</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detectable Human Papillomavirus (HPV) Antibody to Type 11 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 11 at Baseline</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detectable Human Papillomavirus (HPV) Antibody to Type 16 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 16 at Baseline</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Detectable Human Papillomavirus (HPV) Antibody to Type 18 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 18 at Baseline</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Changes in CD4+ Cell Count From Baseline</measure>
    <time_frame>Week 0, 4, 12, 28</time_frame>
    <description>CD4+ cell count at week 0 was subtracted from CD4+ cell counts at each of weeks 4, 12, and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Changes in Plasma HIV-1 RNA From Baseline</measure>
    <time_frame>Week 0, 4, 12, 28</time_frame>
    <description>Plasma HIV-1 RNA at week 0 was subtracted from plasma HIV-1 RNA at each of weeks 4, 12, and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV Antibody Titers to Type 6 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</measure>
    <time_frame>weeks 0, 28, and 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV Antibody Titers to Type 11 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</measure>
    <time_frame>weeks 0, 28, and 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV Antibody Titers to Type 16 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</measure>
    <time_frame>weeks 0, 28, and 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV Antibody Titers to Type 18 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</measure>
    <time_frame>weeks 0, 28, and 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Oral Levels of Serum IgA Before and After the Vaccination Series</measure>
    <time_frame>Weeks 0, 28 and 76</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Infection</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Gardasil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>week 0, 8, 24, 128</description>
    <arm_group_label>Gardasil</arm_group_label>
    <other_name>quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by western
             blot prior to study entry

               -  HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a
                  method other than ELISA is acceptable as an alternative confirmatory test

          -  Anal human papilloma virus DNA PCR-negative for either type 16 and/or type 18 within
             90 days prior to entry

          -  If receiving antiretroviral therapy:

               -  Receipt of antiretroviral therapy for at least 6 months prior to entry

               -  No change in antiretroviral therapy within 30 days prior to entry

               -  CD4 cell count &gt; 200 cells/mm³ within 90 days prior to study entry

               -  HIV-1 RNA &lt; 200 copies/mL within 90 days prior to entry

          -  If not receiving antiretroviral therapy:

               -  CD4 cell count ≥ 350 cells/mm³ within 90 days prior to study entry

               -  No plans to start antiretroviral therapy prior to week 28

          -  Normal anal cytological result, or atypical squamous cell of undetermined significance
             or low-grade squamous intraepithelial lesions (SIL) result within 90 days prior to
             entry

        Exclusion criteria:

          -  Current or history of anal or perianal carcinoma

          -  Anal cytological result of high-grade SIL (HSIL), atypical squamous cells suggestive
             of HSIL, or suggestive of invasive carcinoma at screening or a history of these
             results

          -  Presence of high-grade anal intraepithelial neoplasm (HGAIN) (e.g., AIN 2 or 3, or
             perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma at pre-entry,
             or history of HGAIN

               -  Current or history of anal or peri-anal condyloma is allowed

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Karnofsky performance status 70-100%

          -  Absolute neutrophil count &gt; 750 cells/mm³

          -  Hemoglobin ≥ 9.0 g/dL

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine clearance ≥ 60 mL/min

          -  AST and ALT ≤ 3 times ULN

          -  Total or conjugated (direct) bilirubin ≤ 2.5 times ULN

        Exclusion criteria:

          -  Serious medical or psychiatric illness, active drug or alcohol use, or dependence
             that, in the opinion of the site Investigator, would interfere with adherence to study
             requirements

          -  Serious illness requiring systemic treatment and/or hospitalization within the past 45
             days

          -  Allergy to yeast or any of the components of quadrivalent human papillomavirus (types
             6, 11, 16, 18) recombinant vaccine

          -  Hemophilia

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  See Disease Characteristics

        Exclusion criteria:

          -  Prior splenectomy

          -  Currently receiving anticoagulation therapy other than acetylsalicylic acid

          -  Use of any systemic antineoplastic or immunomodulatory treatment, systemic
             corticosteroids, investigational vaccines, interleukins, interferons, growth factors,
             or IVIG within 45 days prior to study entry

               -  Routine standard of care, including hepatitis A or B, influenza, or pneumococcal
                  and tetanus vaccines are not excluded

               -  Hepatitis C co-infected patients are eligible provided no concurrent initiation
                  of treatment for hepatitis C

          -  Prior receipt of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine or other
             HPV vaccine
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J. Wilkin, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Palefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Clinical AIDS Research and Education (CARE) Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204-4507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser Surgery Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>June 28, 2011</results_first_submitted>
  <results_first_submitted_qc>June 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2011</results_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infection</keyword>
  <keyword>low-grade squamous intraepithelial lesion</keyword>
  <keyword>atypical squamous cells of undetermined significance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gardasil</title>
          <description>Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gardasil</title>
          <description>Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine</title>
        <time_frame>All study visits</time_frame>
        <population>Intention to treat (i.e., received at least one dose of the vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine</title>
          <population>Intention to treat (i.e., received at least one dose of the vaccine)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detectable Human Papillomavirus (HPV) Antibody to Type 6 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 6 at Baseline</title>
        <time_frame>Week 28</time_frame>
        <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Number of participants seropositive for HPV-6 at week 28 among those who were seronegative at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Detectable Human Papillomavirus (HPV) Antibody to Type 6 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 6 at Baseline</title>
          <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.92">Lower one-sided 95% confidence interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longitudinal Changes in CD4+ Cell Count From Baseline</title>
        <description>CD4+ cell count at week 0 was subtracted from CD4+ cell counts at each of weeks 4, 12, and 28.</description>
        <time_frame>Week 0, 4, 12, 28</time_frame>
        <population>Intention to treat population, includes all participants who received at least one dose of vaccine and had assessments at week 0 and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
          </group>
        </group_list>
        <measure>
          <title>Longitudinal Changes in CD4+ Cell Count From Baseline</title>
          <description>CD4+ cell count at week 0 was subtracted from CD4+ cell counts at each of weeks 4, 12, and 28.</description>
          <population>Intention to treat population, includes all participants who received at least one dose of vaccine and had assessments at week 0 and the specified week.</population>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="-81" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="-56" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-72" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longitudinal Changes in Plasma HIV-1 RNA From Baseline</title>
        <description>Plasma HIV-1 RNA at week 0 was subtracted from plasma HIV-1 RNA at each of weeks 4, 12, and 28.</description>
        <time_frame>Week 0, 4, 12, 28</time_frame>
        <population>Intention to treat population, includes all participants who received at least one dose of vaccine and had assessments at week 0 and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
          </group>
        </group_list>
        <measure>
          <title>Longitudinal Changes in Plasma HIV-1 RNA From Baseline</title>
          <description>Plasma HIV-1 RNA at week 0 was subtracted from plasma HIV-1 RNA at each of weeks 4, 12, and 28.</description>
          <population>Intention to treat population, includes all participants who received at least one dose of vaccine and had assessments at week 0 and the specified week.</population>
          <units>copies/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV Antibody Titers to Type 6 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
        <time_frame>weeks 0, 28, and 76</time_frame>
        <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
          </group>
        </group_list>
        <measure>
          <title>HPV Antibody Titers to Type 6 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
          <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
          <units>Milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seropositive Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="58" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="933" lower_limit="525" upper_limit="1657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="613" lower_limit="393" upper_limit="959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336" lower_limit="242" upper_limit="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146" lower_limit="115" upper_limit="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detectable Human Papillomavirus (HPV) Antibody to Type 11 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 11 at Baseline</title>
        <time_frame>Week 28</time_frame>
        <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Number of participants seropositive for HPV-6 at week 28 among those who were seronegative at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Detectable Human Papillomavirus (HPV) Antibody to Type 11 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 11 at Baseline</title>
          <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.93">Lower one-sided 95% confidence interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detectable Human Papillomavirus (HPV) Antibody to Type 16 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 16 at Baseline</title>
        <time_frame>Week 28</time_frame>
        <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Number of participants seropositive for HPV-6 at week 28 among those who were seronegative at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Detectable Human Papillomavirus (HPV) Antibody to Type 16 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 16 at Baseline</title>
          <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.95">Lower one-sided 95% confidence interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detectable Human Papillomavirus (HPV) Antibody to Type 18 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 18 at Baseline</title>
        <time_frame>Week 28</time_frame>
        <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Number of participants seropositive for HPV-6 at week 28 among those who were seronegative at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Detectable Human Papillomavirus (HPV) Antibody to Type 18 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 18 at Baseline</title>
          <population>Per protocol population for a given HPV type requires patients to be seronegative for that type at entry and to have no HPV DNA detected by PCR for that type at entry and screening. Also, patients must have received 3 doses of vaccine.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.89">Lower one-sided 95% confidence interval</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV Antibody Titers to Type 11 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
        <time_frame>weeks 0, 28, and 76</time_frame>
        <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
          </group>
        </group_list>
        <measure>
          <title>HPV Antibody Titers to Type 11 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
          <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
          <units>Milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seropositive Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="42" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1536" lower_limit="1089" upper_limit="2168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="797" lower_limit="520" upper_limit="1221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503" lower_limit="385" upper_limit="658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="151" upper_limit="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV Antibody Titers to Type 16 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
        <time_frame>weeks 0, 28, and 76</time_frame>
        <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
          </group>
        </group_list>
        <measure>
          <title>HPV Antibody Titers to Type 16 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
          <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
          <units>Milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seropositive Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="59" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2005" lower_limit="1215" upper_limit="3309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1225" lower_limit="779" upper_limit="1926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1001" lower_limit="745" upper_limit="1346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" lower_limit="202" upper_limit="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV Antibody Titers to Type 18 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
        <time_frame>weeks 0, 28, and 76</time_frame>
        <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
          </group>
        </group_list>
        <measure>
          <title>HPV Antibody Titers to Type 18 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status</title>
          <population>Intent to treat population, includes all participants who received at least one dose of vaccine</population>
          <units>Milli-Merck units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seropositive Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="39" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="765" lower_limit="446" upper_limit="1313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370" lower_limit="202" upper_limit="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" lower_limit="138" upper_limit="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative Group at Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="27" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Oral Levels of Serum IgA Before and After the Vaccination Series</title>
        <time_frame>Weeks 0, 28 and 76</time_frame>
        <population>Samples for this outcome measure were not analyzed due to loss of funding for the central lab.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Oral Levels of Serum IgA Before and After the Vaccination Series</title>
          <population>Samples for this outcome measure were not analyzed due to loss of funding for the central lab.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gardasil</title>
          <description>Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain / Head/Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Normal ANC or Grade 1 or 2 Neutrophils/Bone (Osteomyelitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specifiy, __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (Asthenia, Lethargy, Malaise)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specifiy, __)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (4.0)">Infection with Normal ANC or Grade 1 or 2 Neutrophils / Upper Airway NOS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Infection with Unknown ANC / Upper Airway NOS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction / Extravasation Changes</sub_title>
                <counts group_id="E1" events="62" subjects_affected="35" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Group Statistician</name_or_title>
      <organization>AMC</organization>
      <phone>501-526-6712</phone>
      <email>jylee@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

